News in Brief May 13 – Goya, Target and More
by Ty Armstrong
Last Updated on June 26, 2017
Goya Hit with Lawsuit Over Canned Octopus
Goya has been hit with a proposed class action claiming that it’s not being honest about its canned octopus. According to the lawsuit, DNA testing revealed that the “octopus” products were actually made from jumbo squid – which is cheaper and more readily available. The complaint says that the substitution is deceitful because it isn’t mentioned anywhere on the packaging.
FDA Issues Strict Warning Labels for Class of Antibiotics
The U.S. Food and Drug Administration has issued an order to put stronger warnings on a type of antibiotics known as fluoroquinolones. The agency announced that the antibiotics come with inherent risks that usually outweigh the benefits for patients, especially when other treatment options are available. Side effects of fluoroquinolones can potentially cause permanent damage to nerves, muscles, joints, tendons and the central nervous system.
Judge Dismisses Target FCRA Suit
Minnesota federal judge Donovan W. Frank decided to dismiss a class action against Target. The suit claimed that Target violated the Fair Credit Reporting Act by including irrelevant information in its employee background check notifications. Frank reasoned that even if Target violated the FCRA, the court couldn’t conclude that the violation was deliberate.
Bloomberg Settles Wage and Hour Lawsuit
Bloomberg has agreed to pay $5.5 million to settle accusations that it underpaid its New York call center employees. The proposed class action claimed that Bloomberg failed to pay its workers for meal breaks and work done after their shifts ended. Up to 160 Bloomberg employees in New York will be able to claim a part of the settlement.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.